Replies to post #1049 on Antares Pharma, Inc. (ATRS)

[Bsav88atty]

Good thoughts, Jab. I wonder when ATRS's patent on its ibuprofen gel expires...anyone? If the patent expires in 2019, 3 years after the anticipated launch, perhaps that would explain the short period of royalty revenues. If ATRS received $750K as a pre-phase three milestone, I suspect that future milestones will be higher. Moreover, I speculate that the FDA approval milestone payment from PFE will be significantly larger than last year's payment from Watson for the FDA's approval of Gelnique. I guess time will tell.